2024 Sponsors

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company’s first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.  

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

Lunit develops AI-powered medical image analysis software via cutting-edge deep learning technology. Our Lunit SCOPE product suite helps researchers and clinicians make accurate and efficient decisions through data-driven imaging biomarkers. Lunit SCOPE IO is our AI-powered analyzer of the tumor microenvironment, purely from H&E, for quantitative immune phenotyping and beyond. Peer reviewed studies employing SCOPE IO have been published in the Journal of Clinical Oncology, Clinical Cancer Research, NPJ Precision Oncology, and more. Lunit SCOPE IHC is our AI-powered analyzer of IHC targets including PD-L1, HER2, and more. Lunit SCOPE IHC currently powers all PD-L1 scoring for Guardant Health’s Galaxy PD-L1 tissue testing. Lunit works with the world’s leading biopharmaceutical companies, CROs, and clinical labs to develop and deploy the next generation of oncology therapeutic biomarkers.

At Median, we transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for sponsors worldwide. To learn more, visit https://mediantechnologies.com/

PPD, part of Thermo Fisher Scientific, provides clinical development and analytical services that enhance customer innovation and productivity. Utilizing patient-centered strategies and data analytics, we cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, patient recruitment, investigator sites and comprehensive laboratory service. To learn more, please visit https://www.ppd.com/

PredxBio is a TechBio company, headquartered in Pittsburgh, harnessing the power of spatial biology to unravel the hidden circuitries of the tumor microenvironment and getting to the “Why?” of cancer. Demonstrating a clear impact today, we have established an impressive accuracy in predicting patient responses to immunotherapy across the most critical cancers. Our ground-breaking platform aims to transform cancer care with next generation spatial analytics and explainable AI, thereby accelerating advancements in drug development and clinical trials. PredxBio opens a new era with far-reaching implications for biomarker discovery and clinical research with promising results in understanding disease progression and response to therapy. For more information please reach us at info@predxbio.com

Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm.

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics.

Immunai's engineering-first platform maps the immune system for the discovery and augmentation of novel therapeutics, through single-cell sequencing, functional genomics, big data and ML. Immunai holds a successful track record of partnering with leading pharmaceutical and biotech companies, academic institutions and hospitals to optimize their preclinical and clinical decision-making. To learn more, please visit https://www.immunai.com/

Founded in 2023, Kincell Bio’s mission is to be a trusted manufacturing services partner for early-stage cell therapy companies by providing access to CMC development and clinical manufacturing services for emerging leaders in cell therapy. 

Headquartered in Gainesville, Florida, Kincell is a technology-forward contract development and manufacturing organization (CDMO) dedicated to streamline analytical development, process development, CMC consulting and early-stage GMP cell therapy manufacturing. Kincell’s primary focus is to aggregate technology, experiences and ambitions to manufacture commercially viable immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK and CAR-M programs.

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology. For more information, visit: https://scailyte.com/

Scimega is a niche Canadian oncology CRO acting in Canada within the context of global cutting-edge oncology trials sponsored by mid-size and smaller biotechs. Skilled in collaborative vendor teaming, Scimega guarantees sponsors the quickest site start-up and highest patient recruitment rate, without sacrificing premium quality data. With an optimal operations design robust enough to address an ever-changing clinical trial landscape, Scimega’s team of Lean Coached oncology experts go above-and-beyond to provide: Local, full-time, permanent hires for exceptional staff quality; An extensive network of Canadian Investigator Sites that frequently emerge among top enrollers, and are activated 50% faster than average for global studies; Optimal site engagement to maximize quality, timely data entry and query resolution; Robust and Lean Scimega methodology and processes are supported by current technology to keep every trial this CRO monitors on the Lean trajectory.

To learn more about the Canadian opportunity or explore an expansion with Scimega, please visit: https://scimega.com/

TD2 provides innovative services for improved and accelerated development of medicines for cancer. Our team has deep experience and understanding in drug development. Preclinical development, combined with regulatory affairs expertise, guides customized clinical trial design and execution. Our capabilities encourage the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. To learn more, visit www.td2inc.com

As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers advanced platforms and end-to-end solutions that enable the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs around the world. For more information visit www.advancedtherapies.com.

Cytovation is a clinical-stage immuno-oncology biotech focused on the development of CyPep- 1, a first-in-class synthetic peptide that drives a systemic and cancer-specific immune response. CyPep-1 has a dual mode of action that includes (1) inhibition of the Wnt/beta-catenin oncogenic pathway, and (2) disruption of cancer cell membranes and exposure of neoantigens to the tumor microenvironment. Building on positive data from a 55-patient Ph 1/2a study, Cytovation is focusing on beta-catenin-driven cancers with metastasis to the liver, an area of very high unmet need.

Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on targeting tumor microenvironment to identify effective mechanisms to kill cancer. A pipeline of novel molecules has been developed using its proprietary platforms. Through internal R&D expertise and partnerships with global biopharmaceutical companies, Elpiscience endeavors to advance the programs with breakthrough value into clinic use. To learn more, please visit www.elpiscience.com.

EvolveImmune Therapeutics is a development-stage immune-oncology company which is pioneering an entirely new category of Precision Oncology medicines designed to overcome cancer cell resistance to current anti-tumor therapies. Our proprietary EVOLVE trispecific T cell engager platform fully integrates T cell costimulation through the CD2 receptor in a single biotherapeutic molecule, to optimize T cells for deep and durable clinical responses. To learn more, please visit https://evolveimmune.com.

Inimmune is a private clinical stage company dedicated to developing immuno-therapeutics. It is focused on advancing its Toll Like Receptor ligand portfolio as vaccine adjuvants, and immuno-therapeutics to be used alone or in combination to treat cancer, allergy, autoimmune disorders and infectious diseases. The company, through its chemistry, formulation and immunology expertise participates in a number of NIH-sponsored research collaborations with leading U.S. based universities developing vaccines to treat a variety of conditions including infectious diseases and opioid addiction. To learn more please visit: https://inimmune.com/

Prokarium is a clinical-stage biopharmaceutical company bioengineering Living Cures through advanced synthetic biology. Our lead program, progressing through US clinical trials for bladder cancer, introduces a single-dose therapy redesigning the treatment paradigm for patients. Prokarium's innovative Living Cures platform aims to transform precision medicine with off-the-shelf programmable therapeutics, establishing a new class of immunotherapies.

Radiant Biotherapeutics is a revolutionary antibody platform company leading the next frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. Radiant’s proprietary Multabody™ platform leverages avidity and multi-specificity simultaneously, to generate highly efficacious Multabodies with superior potency than other antibody platforms. These powerful Multabodies have potential to deliver a new class of biologics to tackle complex, heterogenous diseases, such as cancer, that often have challenging targets and mechanisms. Multabody™ production and manufacturing is flexible, modular and scalable, and leverages standard antibody CMC processes. The ground-breaking efficiency of the platform is driving a novel pipeline of mono-, bi- and tri-specific biologics in multiple therapeutics areas. With offices in Toronto and Philadelphia, Radiant has forged multiple strategic partnerships that validate the Multabody™ platform’s broad scientific and clinical utility. For more, visit radiantbio.com.

Saros Therapeutics is a private, pre-clinical biotech company developing therapies that enhance the immune response against cancer by targeting STING. The technology was engineered to overcome problems of prior STING therapies through cell specific targeting, increased potency and a better route of administration. Successful development of Saros' lead program will bring tremendous benefits to patients with many different types of cancer.

Virogin Biotech is a clinical-stage immuno-oncology company, with a primary focus on innovative HSV-1 based oncolytic virus (OV) and mRNA-based (including self-amplifying RNA/saRNA) therapeutics to elicit robust and durable anti-tumor immune response against solid tumors. Both the platforms exhibit a high degree of complementarity via a mechanism of heterologous prime-boost. Enhanced anti-tumor efficacy has been observed if OV and mRNA tumor vaccines were combined due to (1) modulation of immune-suppressive tumor microenvironment through release of immunological payloads carried by OV, and (2) antigen spread via direct tumor cell lysis triggered by OV infection, which functions like an in situ personalized tumor vaccine. Yet each platform has ‘plug-to-play' features to independently develop novel therapies against cancer & other indications. Our oncolytic HSV-1 platform has two candidates in clinical trials, with our most advanced asset in Phase 2. Candidates from our mRNA platform have also completed preclinical proof of concept.

Akamis Bio is a clinical-stage oncology company aiming to transform treatment of advanced solid tumors by designing novel, systemically administered viruses that can deliver potent, immunomodulatory therapeutics directly into tumors to treat previously intractable cancers.

Annexin Pharmaceuticals is a publicly listed (NASDAQ/First North, Sweden) clinical stage biotech company advancing ANXV (a human recombinant protein Annexin A5 ) first-in-class biologic with a broad therapeutic potential. The company focus is in ophthalmology and oncology incl ADC. Retinal Vein Occlusion is the primary indication in focus. Here ANXV has a potential to become a first in line first in class treatment. The mode of action is non-overlapping to the current standard of care anti-VEGF. The Phase 2 clinical trial in Retinal Vein Occlusion is approved by the FDA and is currently enrolling in the USA. In immunooncology, the company is advancing ANXV as a monotherapy and as a carrier for chemo (Protein Drug Conjugate). The CMC process is optimized and is being prepared for commercial upscaling. The IP portfolio is strong with the key patents recently issued in major territories. Annexin Pharmaceuticals management are open to looking at the full range of strategic options that would facilitate long term development.

Biond Biologics is a private, clinical-stage biotech company, developing a pioneering intracellular drug delivery platform called INspire and innovative Immuno-oncology therapies. INspire, delivers biologics, e.g., nanobodies and proteins for intracellular targets considered hard-to-target such as the RAF, RAS proteins. Our IO pipeline includes three novel biological drugs, BND-22 an anti ILT2/LILRB1 antibody, licensed to Sanofi and is in phase 1; BND-35 an anti ILT3/LILRB4, with phase 1 initiating in H1 2024 and BND-67 - A nanobody based agent targeting CD28 shedding potentially effecting resistance to anti-PD-1 therapy.

Canopy Biosciences, a Bruker company, empowers innovation by providing access to cutting-edge spatial biology and multi-omic tools so biomedical researchers can drive scientific discovery faster. Our proprietary technology ChipCytometry™ is a quantitative multiplex immunofluorescence imaging method for the spatial analysis of complex tissues and mapping of cell populations with single-cell resolution. Supported by Canopy Spatial Services™ with our CLIA-certified laboratory, we provide a unique collection of spatial and single-cell technologies that accelerate the understanding of cellular diversity and interaction. Learn more at canopybiosciences.com

Elephas is developing an ex-vivo technology suite to assess how live tumor fragments (LTFs)TM respond to immunotherapies. We seek to remove the trial-and-error approach to cancer care by harnessing the latest advances in cancer biology, advanced imaging, and artificial intelligence to accelerate drug development and empower clinical decision-making. Our unique approach maintains the native 3-dimensional cellular architecture and micro-environment of the tumor, enabling rapid real-time characterization of live tumor sample response to immunotherapies. To learn more, visit us at www.elephas.com. 

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational AMP immunotherapies intended to precisely target and fully engage the lymph nodes.  ELI-002, a structurally novel investigational AMP therapeutic immunotherapy targeting mutant KRAS-driven solid tumors, is currently in a Phase 2 trial in patients with high relapse risk mKRAS-driven pancreatic cancer.

IMU's platform combines high-resolution immunophenotyping with machine learning analytics and a proprietary population level database, building on of 10+ years of research out of King’s College London, with a world class team of immunologists, data scientists, and operators. IMU is developing a unique and groundbreaking understanding of the immune system that will enable the development of novel biomarkers, with the goal of becoming the gold standard for immune profiling and accelerating product development for cell therapies and new tools for precision medicine.

IN8bio is a clinical-stage biopharmaceutical firm that specializes in advancing gamma-delta T cell therapies to achieve its mission of CANCER ZERO, the safe elimination of all cancer cells in every patient. The company’s DeltEx platform uses allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies designed to effectively identify and eradicate tumor cells. It has three lead product candidates in clinical trials for glioblastoma and leukemia (INB-400, INB-200, INB-100), and a portfolio of preclinical programs for solid tumors.

Invicro, a subsidiary of REALM IDx, is an industry leading imaging CRO and analytics solution provider that supports biopharma companies across all stages of the drug development pipeline from preclinical through Phase 0-IV. Our extensive experience with all imaging modalities and therapeutic areas distinguishes us as a unique core lab service with the ability to manage the most complex of studies, regardless of scale or deliverable requirements. With the ability to advance the standard of care and employ cutting edge image analytics, Invicro has supported over 130 cancer studies, incorporating IO imaging tracers, such as PDL1, CD8, Granzyme-B and other common oncology tracers targeting PSMA, FAP, FDG. Invicro operates out of nine global laboratories, clinics and sites within the United States in Massachusetts, Michigan, California, Connecticut and globally in the United Kingdom, India, Japan and China. For more information visit www.invicro.com.

Invus is a global equity investment firm with an evergreen capital structure, operating out of offices in the U.S., Europe and Asia. Since its founding in 1985, Invus has focused on empowering entrepreneurs and entrepreneurial teams to transform their industries across both public and private equity investments.

LASE Innovation, founded in 2018 and based in Boston, is advancing cell therapy research with their patented LP Cell Barcoding™ technology. LP Cell Barcoding enables massively multiplexed barcoding of cells and the unprecedented ability to connect data across multiple single-cell and omics platforms including flow cytometry, imaging and sequencing. LASE Innovation is developing their flagship LASE Cytometer and LP tagging technology enabling Time-lapse flow™ and Multi-pass flow™ cytometry applications that promise to revolutionize how users approach flow cytometry experiments and researchers connect their data across the myriad of platforms leading to accelerated discoveries for health and disease.

Lumanity applies incisive thinking and decisive action to confront complex situations and deliver transformative outcomes that optimize access to medical advances. Experienced in medical, commercial, and regulatory affairs, Lumanity transforms data and information into real-world insights that power successful commercialization and empowers patients, payers, and regulators to take timely action. For more information, visit: www.lumanity.com

Picture Health’s innovative AI imaging technologies extract unique tumor features from routine clinical radiology or pathology imaging. Our Px Platform can create predictive AI models combining imaging features with multiple data sources, including clinical information and genomic biomarkers. These models enable precise patient selection, regimen analysis, and early response detection. Understand your patient population. Minimize the cost of failed clinical trials. Maximize your pipeline’s potential. See Px in action at Showcase A.

Radiomics is an imaging research organization which focuses on AI powered healthcare, with a unique expertise in Radiomics, Deep Learning & Federated Learning applied to oncology and other therapeutic areas. Founded in 2016, Radiomics has its HQ in LégiaPark in Liege, Belgium and a North American office in Toronto, Canada. For further information, visit www.radiomics.bio

RareCyte provides Precision Biology™ products and services for discovery, translational research and clinical diagnostics. The Orion™ spatial biology platform enables whole-slide highly multiplexed tissue analysis for multiple samples per day. Comprehensive liquid biopsy offerings enable CTC and other rare cell characterization and single cell retrieval for molecular analysis and CDx development.

Specialized in developing genetically engineered mouse models, GenoBioTX proudly offers an inventory of 9000 catalog mouse models and has successfully customized over 19,000 strains for clients. GenoBioTX also provide more than 600 humanized mouse models for drug discovery. Beyond this, GenoBioTX has expanded into pre-clinical CRO services across diverse disease areas, especially immuno-oncology. Our commitment to innovation and client satisfaction continues to drive our success in the dynamic field of drug discovery.

Teiko Bio has developed a transformative end-to-end immune profiling platform on blood and tumor using single-cell mass cytometry. Our leading test, the TokuProfile, analyzes over 1 trillion cellular combinations to map characteristics of response, accelerate clinical pipeline candidates and support identification of novel discoveries. To learn more, visit https://teiko.bio/cancer/

TriStar is a biotechnology company specializing in the provision of quality annotated human oncology biospecimens and integrated, in-house contract research services (IHC, RNA-ISH, WES & RNAseq) for pharma, biotech, and diagnostic developers. Our ethically approved anonymized clinical samples acquired via collaborations with leading UK & European medical centers include pre/post SOC & immunotherapy, and incorporate clinical follow-up, survival & response information. TriStar’s expansive collection of FFPE blocks, tissue microarrays (TMAs), plasma, and digital images include IHC, NGS, RNAseq, GeoMx DSP & CODEX characterized specimens to facilitate a deeper understanding of tumor immune biology and to support drug development research in oncology & immuno-oncology.

Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Veracyte engages in strategic collaborations with biopharmaceutical researchers to provide comprehensive support for their cancer drug development initiatives. In doing so, we offer a wide range of tools and services to support translational research, clinical development, commercial access, and companion diagnostics. 

MedQIA, WorldCare Clinical and DARC, have come together to form Voiant, the industry’s leading clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise. Voiant’s unique AI-based software platform integrates all aspects of clinical trial imaging, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data.

Cytek® Biosciences is a leading cell analysis solutions company advancing the next generation of tools with patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s portfolio includes the Cytek Aurora™, Cytek Aurora™ CS and Cytek Northern Lights™ systems, Amnis® and Guava® products, reagents, software, and services to provide comprehensive solutions for customers.

Leading scientists and researchers turn to Flywheel to accelerate their work and collaborate with ease. Our medical imaging AI platform streamlines the massive tasks of data discovery, aggregation, and curation; automates research workflows; and scales on demand.

HistoWiz accelerates scientific research and discoveries by automating histology and digital pathology solutions. The company is a leading provider of end-to-end solutions for digital pathology, offering comprehensive services from slide creation to digitization, image analysis, and pathology consultations. Its platform, PathologyMapTM, empowers researchers with tools for efficient image management and analysis. Through automation and AI, HistoWiz’s innovations promote a deeper understanding of biology by enabling global collaboration to drive scientific advancement. HistoWiz was founded in 2013 and is headquartered in Long Island City, New York. 

As a CLIA/CAP accredited laboratory, we support translational research and clinical trials. We leverage advanced laboratory technologies to provide diagnostic and discovery modules including histology, spatial biology, digital pathology, image analysis, pathology central review, liquid biopsy, proteomics, genomics, and biomarker discovery and validation.

MERIT is an oncology endpoint expert providing image collection, centralized reading, and data management services for clinical trials since 2012. We have supported hundreds of trials across 58 countries. MERIT partners with CROs as well as pharma and biotech companies to deliver reliable endpoint services in global clinical trials. To learn more, please visit meritcro.com

Noble Life Sciences description : Noble is a preclinical CRO based in Sykesville, Maryland, offering GLP and non-GLP services, including safety and efficacy testing, for the development of novel therapeutics. Our Oncology team has deep experience designing and implementing a variety of animal models to characterize oncology drug candidates for efficacy, pharmacodynamics, pharmacokinetics, toxicity, and bioavailability.

Nona Biosciences specialized in fully human therapeutic antibody technology. Our proprietary Harbour Mice® technology are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform is fully optimized and clinically validated with global patented protection.

RadMD is a radiologist-led imaging provider focusing on blinded central and site reads with a specialty in oncology trials. “We will never lose focus on what has always been the most important task: the image reads. It is the reads that determine if a drug works. Everything else is secondary and supportive of the highest quality reads possible.” Rick Patt, Co-founder

CellGenix and Albumedix, now part of Sartorius -- a trusted partner of the life science and biopharmaceutical industry -- offer developers high-quality, consistent, and dependable raw materials. Join us and discover more about our cytokine, media, and recombinant albumin solutions, and how they can drive your project forward.

Serimmune is an immune intelligence company focused on identifying and exploiting the universe of relationships between antibodies and antigens. Our proprietary technology (SERA) provides a holistic view of the circulating antibody repertoire to identify diverse immunogenic factors in disease and health. Serimmune’s human immunity map is a growing database that can be interrogated to fuel the development of multiplex diagnostics, vaccines, and therapeutics. Serimune is in Santa Barbara, CA with strong ties to University of California Santa Barbara where the SERA technology was originally developed.

Founded in 2012, Slingshot Biosciences is a fast growing life sciences company with a platform technology and paradigm-shifting mission to make synthetic cells the gold standard for all cell-based applications—including diagnostics, adoptive cell therapy development and instrument calibration. Learn more at www.slingshotbio.com

Vivalink offers a Biometrics Data Platform for remote patient monitoring in clinical trials. It combines medical wearable sensors and advanced cloud data services to continuously capture patient vitals and biometrics in virtually any remote setting. Applications include ambulatory cardiac monitoring, neutropenic fever monitoring, and pulmonary hypertension assessment.